High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients.


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
May 2019
Historique:
received: 10 10 2018
revised: 16 01 2019
accepted: 02 02 2019
pubmed: 12 2 2019
medline: 9 8 2019
entrez: 12 2 2019
Statut: ppublish

Résumé

Increasing incidence of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-positive men having sex with men (MSM) has been described in recent years. Phylogenetic analyses of acute HCV infections were undertaken to characterize the dynamics during the epidemic in Paris, and associated sexually transmitted infections (STIs) were evaluated. Sanger sequencing of polymerase gene was performed. Maximum likelihood phylogenies were reconstructed using FastTree 2.1 under a GTR+CAT model. Transmission chains were defined as clades with a branch probability ≥0.80 and intraclade genetic distances <0.02 nucleotide substitutions per sites. STIs detected ≤1 month before HCV diagnosis were considered. Among the 85 studied patients, at least 81.2% were MSM. Respectively, 47.6%, 39.0%, 11.0% and 2.4% were infected with genotypes 1a, 4d, 3a and 2k. At least 91.8% were co-infected with HIV. HCV re-infection was evidenced for 24.7% of patients and STIs for 20.0% of patients. Twenty-two transmission chains were identified, including 52 acute hepatitis C (11 pairs and 11 clusters from three to seven patients). These results revealed strong clustering of acute HCV infections. Thus, rapid treatment of both chronic and acute infections is needed among this population to decrease the prevalence of HCV, in combination with preventive behavioural interventions.

Sections du résumé

BACKGROUND BACKGROUND
Increasing incidence of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-positive men having sex with men (MSM) has been described in recent years. Phylogenetic analyses of acute HCV infections were undertaken to characterize the dynamics during the epidemic in Paris, and associated sexually transmitted infections (STIs) were evaluated.
METHODS METHODS
Sanger sequencing of polymerase gene was performed. Maximum likelihood phylogenies were reconstructed using FastTree 2.1 under a GTR+CAT model. Transmission chains were defined as clades with a branch probability ≥0.80 and intraclade genetic distances <0.02 nucleotide substitutions per sites. STIs detected ≤1 month before HCV diagnosis were considered.
RESULTS RESULTS
Among the 85 studied patients, at least 81.2% were MSM. Respectively, 47.6%, 39.0%, 11.0% and 2.4% were infected with genotypes 1a, 4d, 3a and 2k. At least 91.8% were co-infected with HIV. HCV re-infection was evidenced for 24.7% of patients and STIs for 20.0% of patients. Twenty-two transmission chains were identified, including 52 acute hepatitis C (11 pairs and 11 clusters from three to seven patients).
CONCLUSIONS CONCLUSIONS
These results revealed strong clustering of acute HCV infections. Thus, rapid treatment of both chronic and acute infections is needed among this population to decrease the prevalence of HCV, in combination with preventive behavioural interventions.

Identifiants

pubmed: 30742957
pii: S0924-8579(19)30025-1
doi: 10.1016/j.ijantimicag.2019.02.002
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Pagination

678-681

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Eve Todesco (E)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France. Electronic address: eve.todesco@aphp.fr.

Nesrine Day (N)

Cerballiance Laboratory, Paris, France.

Corinne Amiel (C)

Sorbonne Université, Centre d'Immunologie et de Maladies Infectieuses UMRS CR7, Persistent Viral Infection Team, Inserm U1135, APHP, Groupe Hospitalier Paris Est, Hôpital Tenon, Laboratoire de virologie, Paris, France.

Stéphane Elaerts (S)

Cerballiance Laboratory, Paris, France.

Véronique Schneider (V)

Sorbonne Université, Centre d'Immunologie et de Maladies Infectieuses UMRS CR7, Persistent Viral Infection Team, Inserm U1135, APHP, Groupe Hospitalier Paris Est, Hôpital Tenon, Laboratoire de virologie, Paris, France.

Laurent Roudière (L)

AP-HP, Hôpital Pitié-Salpêtrière, Department of Internal Medicine, Paris, France.

Stéphane Hué (S)

Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

Jean-Yves Liotier (JY)

APHP, Hôpital Bicêtre, Department of Infectious Diseases, Le Kremlin-Bicêtre, France.

Julie Bottero (J)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint Antoine, Department of Infectious Diseases, Paris, France.

Thomas L'Yavanc (T)

Centre de santé sexuelle Le 190, Paris, France; Sorbonne Université, APHP, Hôpital Tenon, Department of Infectious Diseases, Paris, France.

Michel Ohayon (M)

Centre de santé sexuelle Le 190, Paris, France; Sorbonne Université, APHP, Hôpital Tenon, Department of Infectious Diseases, Paris, France.

Daniel Gosset (D)

Centre de santé sexuelle Le 190, Paris, France; Sorbonne Université, APHP, Hôpital Tenon, Department of Infectious Diseases, Paris, France.

Vincent Thibault (V)

Department of Virology, CHU de Rennes, Univ Rennes INSERM IRSET UMR_S 1085, Université Rennes 1, Rennes, France.

Laure Surgers (L)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint Antoine, Department of Infectious Diseases, Paris, France; Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France.

Julie Chas (J)

Sorbonne Université, APHP, Hôpital Tenon, Department of Infectious Diseases, Paris, France.

Sepideh Akhavan (S)

Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Persistent Viral Infection Team, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France.

Annie Velter (A)

Santé publique France, Saint-Maurice, France.

Christine Katlama (C)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Department of Infectious Diseases, Paris, France.

Georges Kreplak (G)

Cerballiance Laboratory, Paris, France.

Anne-Geneviève Marcelin (AG)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France.

Marc-Antoine Valantin (MA)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Department of Infectious Diseases, Paris, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH